VetInject A/S - CVR: 36949740

2022, DKK

22.01.2024

Bruttoresultat

-135'

Primær drift

-155'

Årets resultat

-187'

Aktiver

783'

Kortfristede aktiver

492'

Egenkapital

-285'

Afkastningsgrad

-20 %

Soliditetsgrad

-36 %

Likviditetsgrad

46 %

Resultat

22.01.2024

Årsrapport	2022 22.01.2024	2021 30.05.2023	2020 03.05.2022	2019 03.05.2021	2018 05.08.2020	2017 01.05.2019	2016 17.04.2018	2015 01.05.2017
Nettoomsætning
Bruttoresultat	-135.150	-154.952	-139.239	-142.680	-136.164	-141.024	-119.911	-151.642
Resultat af primær drift	-155.388	-181.936	-166.223	-169.664	-163.148	-168.008	-148.482	-178.433
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	0	0	0	0	0	0	462	628
Finansieringsomkostninger	-31.902	-36.912	-31.099	-21.340	-16.934	-16.430	-125	-150
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	0	0	0	0	0	0	0	0
Resultat	-187.290	-218.848	-197.322	-191.004	-180.082	-184.438	-148.145	-177.955
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

22.01.2024

Årsrapport	2022 22.01.2024	2021 30.05.2023	2020 03.05.2022	2019 03.05.2021	2018 05.08.2020	2017 01.05.2019	2016 17.04.2018	2015 01.05.2017
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	491.208	450.000	450.000	453.406	2.161	0	277	18.867
Likvider	1.224	30.309	94.664	120.255	13.796	44.245	65.301	42.692
Kortfristede aktiver	492.432	480.309	544.664	573.661	15.957	44.245	65.578	61.559
Immaterielle aktiver og goodwill	290.080	310.318	337.302	364.286	391.270	418.254	445.238	473.809
Finansielle anlægsaktiver	0	1.026	1.026	1.026	1.026	1.026	0	0
Materielle aktiver	0	0	0	0	0	0	0	0
Langfristede aktiver	290.080	311.344	338.328	365.312	392.296	419.280	445.238	473.809
Aktiver	782.512	791.653	882.992	938.973	408.253	463.525	510.816	535.368

Aktiver

22.01.2024

Passiver

22.01.2024

Årsrapport	2022 22.01.2024	2021 30.05.2023	2020 03.05.2022	2019 03.05.2021	2018 05.08.2020	2017 01.05.2019	2016 17.04.2018	2015 01.05.2017
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	-284.835	-97.545	121.303	318.625	-90.371	89.711	274.150	422.295
Hensatte forpligtelser	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	151.826	112.403	112.678	110.834	110.655	113.321	19.999	21.406
Kortfristede forpligtelser	1.067.347	889.198	761.689	620.348	498.624	373.814	236.666	113.073
Gældsforpligtelser	1.067.347	889.198	761.689	620.348	498.624	373.814	236.666	113.073
Forpligtelser	1.067.347	889.198	761.689	620.348	498.624	373.814	236.666	113.073
Passiver	782.512	791.653	882.992	938.973	408.253	463.525	510.816	535.368

Passiver

22.01.2024

Nøgletal

22.01.2024

Årsrapport	2022 22.01.2024	2021 30.05.2023	2020 03.05.2022	2019 03.05.2021	2018 05.08.2020	2017 01.05.2019	2016 17.04.2018	2015 01.05.2017
Afkastningsgrad	-19,9 %	-23,0 %	-18,8 %	-18,1 %	-40,0 %	-36,2 %	-29,1 %	-33,3 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	65,8 %	224,4 %	-162,7 %	-59,9 %	199,3 %	-205,6 %	-54,0 %	-42,1 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-487,1 %	-492,9 %	-534,5 %	-795,1 %	-963,4 %	-1.022,6 %	-118.785,6 %	-118.955,3 %
Soliditestgrad	-36,4 %	-12,3 %	13,7 %	33,9 %	-22,1 %	19,4 %	53,7 %	78,9 %
Likviditetsgrad	46,1 %	54,0 %	71,5 %	92,5 %	3,2 %	11,8 %	27,7 %	54,4 %

Resultat

22.01.2024

Gæld

22.01.2024

Årsrapport

22.01.2024

Nyeste:01.12.2022- 31.08.2023(offentliggjort: 22.01.2024)

Information om virksomhedens regnskabsklasse:The annual report of VetInject A/S for 2021/22 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

22.01.2024

Dato for ledelsens godkendelse af årsrapporten:2024-01-15

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of VetInject A/S for the financial year 1 December 2022 - 31 August 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The company’s activity level has been fairly low as a result of the anticipation of the licensor’s initiatives and production, thus keeping operating costs very low, where the company after the licensor’s acquisition of the entire issued share capital on 31 August 2023 has become of member of the Injecto Group. The company still expects to base its business activities on the following basis: Sale of lubrigone plunger stoppers included in prefilled syringes (“PFS”) with preparations for animals with emphasis on dogs, cats, and horses, to syringe manufacturers, where such syringes are manufactured by other companies or by a subsidiary within the Injecto Group and the stoppers will be implemented as an integrated part of their product Sublicense sales of lubrigone plunger stoppers and/or to companies producing veterinarian pharma The plunger stoppers mentioned in points 1 and 2 above can be delivered by the licensor’s and parent company’s subsidiary, Injecto A/S. In this connection the company can benefit from the contacts established by the licensor and parent company and its associated companies with the pharmaceutical industry, where some of those contacts in addition to their production of medicinal preparations for humans also produce medicinal preparations for animals. The licensor's and parent company’s subsidiary, Injecto A/S’, established production line for plunger stoppers for 0. 5 ml PFS in ISO in addition to the production line for stoppers for 1. 0 ml (long) PFS strengthens the basis of the company’s business. Moreover, the ongoing implementation of the production line for plunger stoppers for 1-3 ml (2. 25 ml) pre-fillable PFS will ensure that we can deliver in all three basic ISO measurements for PFS. Due to the licensor's and parent company’s expectation of establishing a larger production of easyject syringes based on the development of the co-operation with PATH (www. path. org) and attraction of funds for this production, the company has – at least for the time being - abandoned the plan of producing combined plunger rods and needle caps, as the company with the above mentioned production of the licensor will have the opportunity to sell an entire syringe for pre-filling in the form of easyject at a competitive price. The additional, thorough tests performed by PATH are expected to postpone the establishment of the production line of easyject. The company foresees an increasing potential for pre-fillable syringes for veterinarian use, partly supported by the increasing number of zoonotic diseases and underpinned by the world-wide focus on those following the COVID-19 pandemic. The decision to await the development of the cooperation between the licensor and PATH mentioned above and the licensor’s decision to take over the company has led to the postponement of a supplementary capitalization of the company. Notwithstanding the foregoing it is the intention of the parent company to secure that the company over time will be a fully operational company, which in principle is independent of the parent company apart from the license contract on arm’s length basis. As a part of the strategic fit between Injecto Group A/S and VetInject A/S it is expected that a key person with the right skills in due time will be employed as the responsible person for the build-up of this interesting business area based on Injecto Group A/S’ patented technology.